CRISPR Therapeutics vs Metagenomi Therapeutics
CRSP and MGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRSP and MGX compare
CRISPR Therapeutics is the larger company, worth 156 times as much as Metagenomi Therapeutics ($4.1B against $26.1M).
CRISPR Therapeutics scores higher on the StockData Score (8 against 6 for Metagenomi Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRSP | MGX |
|---|---|---|
| Size and price | ||
| Market cap | $4.1B | $26.1M |
| Share price | $42.24 | $0.692 |
| Change, 1 year | −19.1% | −62.8% |
| Change, 5 years | −48.8% | – |
| Beta (5Y) | 1.38 | 1.28 |
| Employees | 393 | 119 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 162× | – |
| P/B | 2.5× | 0.3× (better) |
| FCF yield | −9.2% (better) | −320% |
| Growth | ||
| Revenue growth (TTM) | −34.3% | – |
| Revenue growth, 5Y average | 37.3% | – |
| Profitability | ||
| Operating margin | −2115% | – |
| Net margin | −1812% | – |
| FCF margin | −1497% | – |
| Return on equity | −25.6% (better) | −69.4% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 16.21 (better) | 3.43 |
| Altman Z-score | 1.78 (better) | −4.66 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Buyback yield | −2.7% | – |
| Shareholder yield | −2.7% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 78.9% | 16.6% |
| Held by insiders | 2.7% | 10.4% |
| Insider net buying, 12 months | −$17.9M | −$9.7K (better) |
| Short interest, % of float | 18.3% | 3.9% |
Go deeper
- CRSP stock overview
- CRSP income statement
- CRSP valuation and score
- MGX stock overview
- MGX income statement
- MGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.